179 related articles for article (PubMed ID: 31332058)
1. Impact of Triazole Therapeutic Drug Monitoring Availability and Timing.
McCreary EK; Bayless M; Van AP; Lepak AJ; Wiebe DA; Schulz LT; Andes DR
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332058
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients.
John J; Loo A; Mazur S; Walsh TJ
Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):881-895. PubMed ID: 31550939
[No Abstract] [Full Text] [Related]
5. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
McCreary EK; Davis MR; Narayanan N; Andes DR; Cattaneo D; Christian R; Lewis RE; Watt KM; Wiederhold NP; Johnson MD
Pharmacotherapy; 2023 Oct; 43(10):1043-1050. PubMed ID: 37459118
[TBL] [Abstract][Full Text] [Related]
6. [Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].
Scodavolpe S; Quaranta S; Lacarelle B; Solas C
Ann Biol Clin (Paris); 2014; 72(4):391-404. PubMed ID: 25119797
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring for triazoles.
Hope WW; Billaud EM; Lestner J; Denning DW
Curr Opin Infect Dis; 2008 Dec; 21(6):580-6. PubMed ID: 18978525
[TBL] [Abstract][Full Text] [Related]
8. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
[TBL] [Abstract][Full Text] [Related]
9. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
11. Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients.
Negri CE; Gonçalves SS; Sousa ACP; Bergamasco MD; Martino MDV; Queiroz-Telles F; Aquino VR; Castro PTO; Hagen F; Meis JF; Colombo AL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893772
[No Abstract] [Full Text] [Related]
12. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
14. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
[TBL] [Abstract][Full Text] [Related]
15. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
[TBL] [Abstract][Full Text] [Related]
16. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole Therapeutic Drug Monitoring in a Regional Hospital Setting.
Lindsay PJ; Bond SE; Norris R; Marriott DJ; Miyakis S
Ther Drug Monit; 2016 Dec; 38(6):804-807. PubMed ID: 27548694
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.
Dolton MJ; Ray JE; Marriott D; McLachlan AJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):2806-13. PubMed ID: 22391534
[TBL] [Abstract][Full Text] [Related]
20. Safety of triazole antifungal drugs in patients with cancer.
Cronin S; Chandrasekar PH
J Antimicrob Chemother; 2010 Mar; 65(3):410-6. PubMed ID: 20035021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
